Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,880.00
Bid: 1,874.00
Ask: 1,880.00
Change: -6.00 (-0.32%)
Spread: 6.00 (0.32%)
Open: 1,814.00
High: 1,880.00
Low: 1,814.00
Prev. Close: 1,886.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition and strategic partnership

23 Feb 2017 07:00

RNS Number : 6110X
Genus PLC
23 February 2017
 

 

 

 

For immediate release 23 February 2017

Genus plc

('Genus' or the 'Group')

 

Acquisition and Strategic Partnership

Genus acquires Hermitage's genetic assets and enters into a strategic partnership

 

Genus, a leading global animal genetics company, and Hermitage, one of the longest established pig breeding companies in Europe, are pleased to announce that they have signed an agreement to enter into a strategic partnership covering the supply of porcine genetics in several markets.

 

PIC, Genus's porcine division, will acquire the genetic rights and intellectual property of Hermitage. Hermitage will also become a strategic supply chain and distribution partner for PIC. In addition, PIC will acquire certain Hermitage customer relationships in various geographies including Russia, the US and several European countries. The transaction is subject to a number of closing conditions which are expected to be fulfilled by the end of March 2017.

 

The partnership combines PIC's genetics expertise and quality, and Hermitage's supply chain network and operational excellence. This combination will strengthen PIC's ability to deliver genetic improvement in Europe and provide customers of both PIC and Hermitage with access to top-tier genetics and optimal technical and health services.

 

Hermitage was established in 1958 in Ireland and is one of the longest established porcine breeding and genetics companies in Europe. Over the years, Hermitage has grown into a multinational porcine breeding company serving pig producers in Europe and other international markets with high-health breeding stock. Hermitage's infrastructure includes nucleus farms and boar studs in Ireland and across Europe, as well as multiplication partners in key international territories.

 

Commenting on the transaction, Karim Bitar, Chief Executive of Genus, commented:

 

"The partnership with Hermitage is an ideal fit with our porcine strategy. It will provide Genus with the opportunity to accelerate genetic improvement by combining the PIC and Hermitage gene pools. In addition, Hermitage's strong supply chain and customer-service oriented team will strengthen our ability to serve pig producers efficiently and reliably."

 

Ned Nolan, owner of Hermitage, added:

 

"This is an exciting step for Hermitage, as we join forces with a global pioneer in our field. Our partnership with PIC will allow the continued use of the Hermitage gene pool to provide enhanced genetics to our global customer base. Hermitage shares PIC's values of pioneering genetic improvement for customers and we look forward to collaborating with PIC's team."

 

For further information, please contact:

 

Genus Tel: +44(0)1256 345970

Karim Bitar, Chief Executive

Stephen Wilson, Group Finance Director

Buchanan Tel: +44(0)207 466 5000

Charles Ryland /Vicky Hayns

 

This announcement is available on the Genus website www.genusplc.com

 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across all livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

 

Genus's worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

About Hermitage

Hermitage was established in 1958 by the Nolan Family. Pedigree Landrace and Large White lines were purchased internationally and developed and selected with the support of Irish Government Central Test Stations in the 60s, 70s and 80s. Over the last 30 years Hermitage Genetics has expanded its Landrace, Large White, Duroc, Pietrain and Maxgro lines, becoming a pig breeding company dedicated to efficient and profitable pig production worldwide. Hermitage top class production facilities support customers across Europe, North America and Asia.

 

Hermitage has developed a science-based breeding program that drives genetic progress focused on traits that are of economic importance to the pig producer. Hermitage now tests over 30,000 pigs per year for lean efficient growth and collects data from more than 22,000 pure-bred sows at the genetic nucleus level. This data is analysed by Hermitage's proprietary BreedDirect BLUP software program and offered by Hermitage to customers through an online data portal. Hermitage Group was advised on the transaction by Investec Corporate Finance in Dublin.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQOKBDDDBKBABB
Date   Source Headline
2nd Jun 20177:00 amRNSTotal Voting Rights
1st Jun 20177:05 amRNSUpdate Regarding The Milk Pension Fund
2nd May 20173:00 pmRNSTotal Voting Rights
12th Apr 20174:48 pmRNSDirector/PDMR Shareholding
3rd Apr 20172:00 pmRNSTotal Voting Rights
3rd Apr 20177:00 amRNSSUCCESSFUL LEGAL OUTCOME FOR GENUS
15th Mar 20175:15 pmRNSDirector/PDMR Shareholding
15th Mar 201712:00 pmRNSDirector Declaration
1st Mar 201710:09 amRNSDirector/PDMR Shareholding
23rd Feb 20174:20 pmRNSCorrection of Record Date
23rd Feb 20177:00 amRNSInterim Results
23rd Feb 20177:00 amRNSAcquisition and strategic partnership
7th Feb 20174:00 pmRNSHolding(s) in Company
1st Feb 20172:00 pmRNSBlock listing Interim Review
13th Dec 20163:39 pmRNSDirector/PDMR Shareholding
1st Dec 20162:00 pmRNSTotal Voting Rights
17th Nov 20162:01 pmRNSResult of AGM
17th Nov 20167:00 amRNSAGM - Trading Update
1st Nov 20164:00 pmRNSTotal Voting Rights
31st Oct 20163:47 pmRNSAnnual Report and Annual General Meeting
26th Oct 20164:00 pmRNSHolding(s) in Company
11th Oct 20164:08 pmRNSDirector/PDMR Shareholding
3rd Oct 20166:09 pmRNSBlock Listing and Additional Listing
3rd Oct 20165:57 pmRNSTotal Voting Rights
29th Sep 20165:00 pmRNSDirector/PDMR Shareholding
15th Sep 20165:00 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
8th Sep 20167:00 amRNSPreliminary Results
7th Sep 20167:00 amRNSNON-EXECUTIVE DIRECTOR RETIREMENT
1st Sep 20164:17 pmRNSTotal Voting Rights
15th Aug 20167:00 amRNSFINAL JURY DECISIONS IN US LITIGATION
12th Aug 20167:00 amRNSFURTHER DECISIONS IN US LITIGATION
11th Aug 20167:00 amRNSFIRST DECISIONS IN US ANTI-TRUST LITIGATION
1st Aug 20169:20 amRNSBlock listing Interim Review
1st Aug 20169:09 amRNSTotal Voting Rights
27th Jul 20167:00 amRNSSigns exclusive licence for tech. to combat BRD
15th Jul 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
1st Jul 20163:10 pmRNSTotal Voting Rights
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
1st Jun 20162:00 pmRNSTotal Voting Rights
18th May 20167:00 amRNSExclusive Licence for Leading Gene Editing Tech
3rd May 20162:29 pmRNSTotal Voting Rights
13th Apr 20163:13 pmRNSDirector/PDMR Shareholding
1st Apr 20163:31 pmRNSDirector/PDMR Shareholding
9th Mar 20165:03 pmRNSDirector/PDMR Shareholding
4th Mar 20169:30 amRNSBOARD APPOINTMENT
3rd Mar 20162:00 pmRNSDirector/PDMR Shareholding
1st Mar 20165:17 pmRNSDirector/PDMR Shareholding
23rd Feb 20167:00 amRNSINTERIM RESULTS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.